|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
Glance at last issue:
/ f! t/ J A8 E( K8 W: O1 v$ [0 w1 m4 u9 T/ `" R1 p4 u* K3 L9 J
"The field yet remains a mystery and we haven’t figured out its exact effects, safety, side effects and even the right dosage. It could result in serious problems."--Korean Medical Association.
; l3 @. ^) m7 I% c# d% D$ V
# ?3 L3 }4 S0 `8 l9 I1 k7 h"We know reprogramming resets the genome [of the reprogrammed cell] globally. What we’ve learned by working with John is that lincRNAs play essential roles in the reprogramming process. We’ve even identified one lincRNA that enhances reprogramming, which is tantalizing evidence that we can make reprogramming more efficient by harnessing lincRNAs. Our groups came together to answer a question that neither group could answer alone."--George Daley of HSCI and Children’s Hospital.& X" `5 ~; k( ]3 V9 M
# M* l0 P: B j% B
"So we don't need to take skin cells and put it into a pluripotent stem cell. That is inefficient in terms of time. There are also concerns that they might form a tumor, and the fact that we bypass that makes it more feasible for transplants."--Mick Bhatia of the McMaster's Stem Cell and Cancer Research Institute in the Michael G. DeGroote School of Medicine.
( d6 c: O( v- o: G$ D4 v1 ^2 A4 I2 Z! }! h8 y
"I think there are exciting aspects in terms of this potentially being a much safer approach than going back through embryonic stem cells...Bhatia's approach detours around the pluripotent stem cell stage and thus avoids many safety issues, increases efficiency, and also has the major benefit of producing adult-type l blood cells instead of fetal blood cells, a major advantage compared to the thus far disappointing attempts to produce blood cells from human ESCs or IPSCs."--Cynthia Dunbar, head of the molecular hematopoiesis section of the National Heart, Lung and Blood Institute of the National Institutes of Health.* S3 M8 h) {# ^9 @6 I1 _
! E; y% ]- c6 R6 k"Although much public interest has been focused on the use of stem cells for tissue replacement, we believe that in many clinical areas their major benefit will be to allow us to model diseases in the culture dish. Such cell-based models can generate new knowledge about the disease process itself, while also opening the way to high-throughput screening for test drug candidates."--Christopher E. Henderson, PhD, Director of the Columbia Stem Cell Initiative and Co-Director of the Columbia Motor Neuron Center.* [9 U& T/ Q5 I; _
7 Q8 r$ u$ V; k7 z" y* A& P7 [
“This groundbreaking work from Mick Bhatia’s lab is both fascinating and important. It heralds a new age by discovering a role for ‘directed differentiation’ in the treatment of cancers and other disorders of the blood and immune system.”--Samuel Weiss, professor and director, Hotchkiss Brain Institute, University of Calgary.' v8 d. y! [# X0 n! {/ A
7 G2 B$ d+ n, K8 g- n9 e4 I"It takes us a step along the line to believing that you can produce anything from almost anything."--Ian Wilmut, director of the MRC Centre for Regenerative Medicine in Edinburgh.
" `5 \- R# I* e6 i- w( ]
; ]' X6 b5 e0 D"The journey from a zygote to a specialized blood cell is very long. The journey from a fibroblast to a blood cell in a petri dish may take a very different route."--George Daley.+ Y, T; V6 q" Y8 p' ], W( D" ^
7 ^; C! \" ?5 Y2 p"We can't categorically say this is attributable to the stem cell infusion. However, we and Sasha's therapist feel the improvement has potentially been at a faster rate than it may have occurred, or in comparison with other children with similar abilities."--Parents of Sasha Browne, 3 years, who is infused with stem cells from her own umbilical cord to treat cerebral palsy.7 G* Q8 ~- X/ c
! n; t' d: V# I# @2 z
“I find it so wild. You go from nobody being able to do this to everybody being able to do it.”--Dr. Richard Klausner, a former head of the National Cancer Institute who is now a managing partner in the Column Group, a venture capital firm.
7 G: A+ l% x) D* G. i5 i' C- c+ _( L, L9 @4 Y) |
"Looking at all the current evidence, it's impossible to decide whether adult or embryonic stem cells will ultimately prove more successful in treating disease. Adult cells may be better for some jobs, embryonic cells for others - we simply can't tell yet, and there are downsides to both technologies. For the moment, we must pursue both lines of research."--Professor Richard Gardner, from Oxford University, who chairs the Royal Society committee on stem cell research.
N8 ?# ~+ O; l; u) Z: a' R( g4 U4 R5 \
“This finding gives us another set of fingers to play on the genomic piano that controls the ‘music’ of cellular reprogramming.”--John Rinn of the Broad Institute and Beth Israel Deaconness Medical Center." @$ w# |- ]3 W$ d7 d' v
' s7 c& @7 d+ N' e/ t7 u
' K" y [) [6 h9 R9 [4 _- oThis issue:
% [: C! g+ F* i* G$ _$ j5 ]" l3 j ]4 E+ m) e
附会议信息、2011年部分干细胞日历" a2 Q/ l0 J7 u
F, E9 t" w3 }6 H, `
Video news:
9 b. d2 k& {4 _* Q$ |7 M' o% V% D. w" e! X) X
New Stem Cell Treatment for Type-1 Diabetes
2 M+ E2 z1 B5 l, Qhttp://www.redorbit.com/news/vid ... es/33447/index.html |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2010-11-15 17:51
